000275939 001__ 275939
000275939 005__ 20240229154948.0
000275939 0247_ $$2doi$$a10.2147/CLEP.S406606
000275939 0247_ $$2pmid$$apmid:37153073
000275939 0247_ $$2pmc$$apmc:PMC10162394
000275939 0247_ $$2altmetric$$aaltmetric:147256314
000275939 037__ $$aDKFZ-2023-00927
000275939 041__ $$aEnglish
000275939 082__ $$a610
000275939 1001_ $$00000-0003-4139-1979$$aTichanek, Filip$$b0
000275939 245__ $$aSurvival in Lung Cancer in the Nordic Countries Through A Half Century.
000275939 260__ $$aAlbany, Auckland$$bDove Medical Press$$c2023
000275939 3367_ $$2DRIVER$$aarticle
000275939 3367_ $$2DataCite$$aOutput Types/Journal article
000275939 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1683709431_9238
000275939 3367_ $$2BibTeX$$aARTICLE
000275939 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000275939 3367_ $$00$$2EndNote$$aJournal Article
000275939 500__ $$a#LA:C020#
000275939 520__ $$aLung cancer is often diagnosed at an advanced stage and survival has been poor, although long-term studies have been rare. We analyzed data on survival in lung cancer from Denmark, Finland, Norway, and Sweden over a 50-year period (1971-2020).Relative 1- and 5-year survival data were obtained from the NORDCAN database for 1971-2020. We used generalized additive models to estimate survival trends over time and uncertainty of these estimates. We additionally calculated conditional survival from the 1st to 5th year (5/1-year), estimated annual changes in survival rates, and determined significant breaking points.In 2016-2020, 5-year survival rate for lung cancer was best for Norwegian men (26.6%) and women (33.2%). The sex difference was significant and it was found for each country. Survival improved modestly until the year 2000, after which time survival curves increased steeply and kept the linear shape to the end of follow-up, indicating consistent improvement in survival. Survival curves for 1- and 5/1-year survival were almost superimposable, indicating that deaths in the first year were approximately as many as in the subsequent 4 years, thus marking sustained long-term survival.We could document a positive development in lung cancer survival with steep upward trends after the year 2000. Intensions for curative treatment have been increasing and the outcomes have been improving with the help of novel imaging methods. Pathways for facile patient access to treatment have been instituted. Close to 90% of the patients are ever smokers. National anti-smoking acts and alerting people who smoke about early symptoms may be beneficial, as metastatic lung cancer remains difficult to cure.
000275939 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000275939 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000275939 650_7 $$2Other$$aconditional survival
000275939 650_7 $$2Other$$alung cancer
000275939 650_7 $$2Other$$arelative survival
000275939 650_7 $$2Other$$asmoking
000275939 650_7 $$2Other$$asurgery
000275939 650_7 $$2Other$$atreatment
000275939 7001_ $$0P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aFörsti, Asta$$b1$$udkfz
000275939 7001_ $$aHemminki, Otto$$b2
000275939 7001_ $$00000-0001-7103-8530$$aHemminki, Akseli$$b3
000275939 7001_ $$0P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aHemminki, Kari$$b4$$eLast author$$udkfz
000275939 773__ $$0PERI:(DE-600)2494772-6$$a10.2147/CLEP.S406606$$gVol. 15, p. 503 - 510$$p503 - 510$$tClinical epidemiology$$v15$$x1179-1349$$y2023
000275939 909CO $$ooai:inrepo02.dkfz.de:275939$$pVDB
000275939 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000275939 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000275939 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000275939 9141_ $$y2023
000275939 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-10-14T20:47:13Z
000275939 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-10-14T20:47:13Z
000275939 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-11
000275939 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-11
000275939 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-11
000275939 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-11
000275939 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN EPIDEMIOL : 2022$$d2023-08-22
000275939 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-22
000275939 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-22
000275939 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-22
000275939 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2022-10-14T20:47:13Z
000275939 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-22
000275939 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-22
000275939 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-22
000275939 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-22
000275939 9202_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000275939 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000275939 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000275939 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x2
000275939 980__ $$ajournal
000275939 980__ $$aVDB
000275939 980__ $$aI:(DE-He78)B062-20160331
000275939 980__ $$aI:(DE-He78)HD01-20160331
000275939 980__ $$aI:(DE-He78)C020-20160331
000275939 980__ $$aUNRESTRICTED